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Background: Indolent systemic mastocytosis (ISM) is the most 
prevalent primary mast cell disorder and is associated with a variety 
of mast cell activation symptoms refractory to anti-histamine therapy. 
Midostaurin, a protein kinase inhibitor of KIT-D816V, has been 
recently found to reduce symptoms in aggressive systemic 
mastocytosis.   
Methods:  We conducted an open-label, nonrandomized, single-
center, phase 2 trial of oral midostaurin at a dose of 100 mg twice 
daily for 24 weeks in 20 ISM patients with severe mediator 
symptoms. The primary outcome was the symptomatic response rate 
according to the mastocytosis symptom assessment form (MSAF) 
sumscore after 12 weeks of treatment. Secondary endpoints included 
the persistence of symptoms after 24 weeks, disease specific quality 
of life (MQLQ) and the effects on serum tryptase, bone marrow and 
skin infiltration.  
Findings: Symptom severity at week 12 showed a statistical 
significant median 35% (P< 0.001; IQR: 16% - 56%) reduction that 
lasted until week 24, with the strongest effects on fatigue and 
musculoskeletal pain. Disease specific quality of life improved 
significantly (P< 0.001, median improvement 29%, IQR 16% - 47%) 
after 24 weeks. These effects were accompanied by a sharp 
reduction in tryptase levels within 4 weeks of treatment (from 36.0 to 
15.5 ug/l, P< 0.001), an improvement of skin infiltration in 80% and a 
modest decrease in bone marrow mast cell infiltration in 50% of 
patients after 24 weeks. The most common adverse events were 
grade 1-2 nausea (80%) resulting in 3 patients dropping out, 
headache (50%) and diarrhea (35%).   
Conclusions: We find midostaurin to be effective, safe and 
reasonably well tolerated treatment for mediator release symptoms 
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Mastocytosis is a spectrum of diseases characterized by an 
increased number of mediator-releasing monoclonal mast cells 
infiltrating multiple organ systems. The treatment and management 
of mastocytosis patients is largely dependent on the classification of 
their disease.1,2 Indolent systemic mastocytosis (ISM) is the most 
predominant category, with mast cell infiltration of - in particular - the 
bone marrow, gastrointestinal tract and skin, but – by definition - no 
resulting organ dysfunction.(3) For most ISM patients the mast cell 
burden will remain stable throughout a near-normal life expectancy. 4 
Unfortunately, the quality of life can be severely affected as 
many ISM patients suffer from debilitating mast cell activation 
symptoms. 5 Here, activated mast cells release mediators inducing a 
wide spectrum of chronic and paroxysmal symptoms, such as 
flushing, pruritus, anaphylaxis, fatigue, depression and 
osteoporosis.6, 7 Anti-histaminic and mast cell stabilizing agents are 
effective in treating most of these symptoms. However, even with 
therapy over 70% ISM patients experience an impaired quality of life 
due to refractory symptoms such as fatigue, illustrating the large 
unmet therapeutic need.5  Moreover, esthetically displeasing skin-
infiltrates such as urticaria pigmentosa (UP) are present in 
approximately 45-70% of ISM patients8,9 and are notoriously 
treatment resistant, often relapsing after psoralen and ultraviolet A 
therapy within 2 to 8 months.10 
Key in the pathogenesis of mastocytosis are the activating 
mutations (typically KIT D816V) in the Kit receptor that lead to 
unrestricted activity of its intrinsic tyrosine kinase activity and 
subsequent autophosphorylation.11 Kit receptor signaling facilitates 
mast cell proliferation and mediator release, including IgE-mediated 
degranulation.12 Preclinical studies have shown that tyrosine kinase 
inhibitors targeting Kit can inhibit proliferation and induce apoptosis in 
mast cells.13-15 The protein kinase inhibitor PKC412 (midostaurin) 
can inhibit the D816V mutated KIT kinase and additionally inhibit IgE-
mediated degranulation through its action on protein kinase C.15,16 
Recently completed studies of midostaurin in the aggressive forms of 
SM resulted in an overall response rate of 60-71% and a major 
response rate of 45-57%, whereas adverse events related to 




diarrhea.17,18 In particular, mast cell activation symptoms rapidly 
responded to treatment with midostaurin, often preceding the 
decrease in mast cell infiltration. These observations suggest that 
midostaurin has both mast cell depleting and mast cell stabilizing 
properties with manageable side effects, prompting speculation on its 
usefulness in ISM.17,19 
We therefore conducted a phase 2 trial in ISM patients with 
severe mast cell activation symptoms refractory to anti-histaminic 
and mast cell stabilizing treatment to study the efficacy and safety of 
midostaurin. We will show that the drug is safe and effective in 
symptom-reduction with simultaneously fast and marked improved 
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This is an open-label, nonrandomized, single-centre, phase 2 trial. 
Eligible patients were contacted and included based on their 
geographic proximity to the University Medical Centre Groningen.  
Patients at least 18 years of age were eligible if a diagnosis of KIT 
D816V+ indolent or smoldering systemic mastocytosis according to 
the World Health Organization criteria was present. 3 In addition,  a 
serum tryptase ≥20 μg/l was required, and severe mediator-related 
symptoms refractory to H1 and H2 blocking drugs defined as a pre-
study mastocytosis symptom assessment form (MSAF) score of 4 or 
more on 3 non-related items, or a pre-study score of 5 or more on 2 
non-related items (one item from the scoring list can be replaced by 
flushes 7 or more per week or anaphylactic attacks 1 or more per 
month). In addition, all men of reproductive potential and women of 
child-bearing potential had to practice effective contraception. 
Excluded from the study were pregnant or nursing women, patients 
diagnosed with advanced aggressive mastocytosis, another 
malignancy unless they were disease-free for at least 5 years, or had 
a diagnosis of non-melanoma skin cancer. Finally patients were 
excluded who were suffering serious comorbidity interfering with 
therapy compliance and follow-up compliance. The patient accrual 
process is demonstrated in Figure 1. This study was approved by the 
University Medical Centre Groningen Institutional Review Board and 
conducted in accordance with the principles of the Declaration of 
Helsinki. All patients gave written informed consent before study 






All anti-histamine and mast cell stabilizing drugs that the patients 
were taking were continued. Midostaurin was supplied by Novartis 
(Basel, Switzerland) as capsules of 25 mg, and had to be taken orally 
at the dose of 100 mg twice a day. Patients received midostaurin 
continuously from day 1. Premedication with anti-emetic 5-HT3 
receptor antagonists was started for all patients two hours before 
midostaurin intake and adjusted after two weeks according to 
symptoms of nausea and vomiting. After 24 weeks of treatment, a 2 
month drug free wash-out period was introduced. Patients with a 
relapse of symptoms and an increase in tryptase levels were allowed 
to restart the drug during a follow-up phase. Toxicities and adverse 
events were evaluated using the Common Terminology Criteria for 
Adverse Events (CTC) Version 4.03. During the entire trial dose 
modifications were allowed in case of toxicity. Patients who 
developed grade 3 or 4 toxicity had to discontinue therapy with 
midostaurin until the adverse event recovered to grade less than or 
equal to 2. If toxicity did not resolve within 3 weeks, therapy was 
discontinued. 
Assessments and measurement tools 
Baseline studies included a complete physical examination, complete 
blood count, a comprehensive biochemistry panel (including liver 
function tests), and measurements of mast cell load. Serum tryptase 
levels were determined using the B12 assay (ImmunoCAP Tryptase, 
Thermo Fisher Scientific, Uppsala, Sweden). Urinary excretion of 
methylhistamine (MH) and methylimidazole acedic acid (MIMA) were 
determined as described previously.20,21 Urine samples were 
collected after an overnight fast, discarding the first voiding after 
wakening. During the 24h before urine collection, patients were 
asked to refrain from histamine-rich foods and drinks.   
Hepatosplenomegaly and lymphadenopathy were documented by 
ultrasound. Skin involvement was documented using the Scoring 
Mastocytosis (SCORMA) scoring system.22)The SCORMA system 
was adapted by using only the skin-related measurement tools, parts 
A and B, preventing interference of mast cell release symptoms on 
the scoring of skin involvement.22 Bone marrow mast cell infiltration 
together with immunophenotyping and molecular analysis was 
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immunophenotyping and KIT D816V mutation analysis were 
performed as described previously.23 
Patients were seen at week 1, 2 and 4 and subsequently monthly 
unless earlier visits were deemed necessary. A complete blood count 
and comprehensive biochemistry panel were obtained at least every 
4 weeks. Symptom severity was self-monitored weekly using the 
mastocytosis symptoms assessment form (MSAF).(5) Quality of life 
was measured at baseline and at weeks 12 and 24 using the general 
SF36 general health questionnaire, and the mastocytosis quality of 
life questionnaire (MQLQ).5,24 The extent of bone marrow mast cell 
infiltration was quantified in biopsies and aspirates, prior to and 24 
weeks after treatment. 
 
Endpoints and safety 
The primary objective of the study was to assess symptomatic 
response rate according to the MSAF sumscore after 12 weeks of 
midostaurin treatment. Secondary endpoints were the persistence of 
symptoms after 24 weeks of midostaurin treatment, changes in 
quality of life at weeks 12 and 24 in combination with the changes in 
mast cell load as assessed by the percentage change in bone 
marrow mast cell infiltration, serum tryptase, skin infiltration, 
lymphadenopathy and hepatosplenomegaly.  
 To ensure safety, an interim analysis focussing on adverse 
events, especially hematologic toxicity, was performed by the 
principal investigator after the first 10 patients had a follow-up of at 
least 12 weeks. Although no formal stopping rule was designed, 
standard good quality clinical practice allowed for early termination of 
the study in case of excess toxicity or unsatisfactory risk/benefit ratio 
of the therapy, as judged by study staff and involved treating 
physicians.  
Statistical analysis 
This is a phase 2 proof-of-concept study and therefore a formal 
sample size calculation was not performed. MQLQ scores were 
transformed to a 0 (worst) to 100 (best)scale to facilitate comparison 
with SF36 scores. In order to calculate aggregate scores for the 




handled using the last observation carried forward method. 
Questionnaires missing >10% of the items were not analysed. 
Intention-to-treat analyses were used unless otherwise specified. 
Descriptive statistics were used to assess response; Mann-Whitney 
U test and Wilcoxon signed rank test were used for statistical 
comparisons.  
Role of the funding source 
The study was investigator initiated, conceived and designed by the 
Groningen Mastocytosis Centre and was performed and monitored in 
collaboration with an independent trial coordination center (TCC, 
Groningen, The Netherlands). Novartis (Novartis Pharma, Basel, 
Switzerland) funded the study and provided study drugs. All authors 
had full access to all data in the study and had final responsibility for 
the decision to submit for publication. 
Results 
Patients 
Starting June 2012, 248 ISM and SSM patients were screened on 
symptom severity using the MSAF. Out of the 168 that returned filled 
out questionnaires, 55 patients met the symptom severity inclusion 
criterion and were contacted in order of geographic distance to the 
treatment facility.  Between September 2013 and August 2015, 
twenty ISM patients were included. The patient selection and accrual 
process is further detailed in Figure 1 and the baseline 
characteristics of those included are displayed in Table 1. Briefly, the 
mean age of included was patients was 49 ± 12 years old, there was 
an almost even male-female proportion (45-55%) and all but five 
patients exhibited UP (75%). During the trial three patients dropped 
out due to adverse events, all related to nausea, before week 12. 
Efficacy: symptom severity  
The primary efficacy endpoint of MSAF measured symptom severity 
at week 12 showed a statistical significant median 35% (P< 0.01; 
IQR: 16% - 56%) reduction in symptom severity, resulting in an 
improvement in symptoms for 75% (n=15) of the patients. Symptom 
severity scores further improved to an average 38% reduction at 
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frequency of flushing decreased from a median of 5 flushes per week 
at baseline to 1 flush per week after 24 weeks of treatment. 
Anaphylactic-like mastocytosis “attacks” were present in 3 patients at 
baseline, for one of these patients the monthly occurrence dropped 
from 60 to 23, strongly affecting the ability to perform basic daily 
activities. In the remaining two patients these attacks stopped 
completely, coming down from 20 and 3 attacks per month 
previously. The strongest improvement in chronic mediator release 
symptoms was seen in the symptoms fatigue and musculoskeletal 
pain, as evidenced by a median 4 point and 3.5 point difference in 
score on a 0-10 scale after 24 weeks of treatment. Conversely, there 
was a median 0.5 point increase in reported nausea and vomiting 
symptoms after 24 weeks. The symptom specific effect of 
midostaurin is further illustrated in Figure 3. 
Efficacy: quality of life 
The secondary efficacy endpoint of MQLQ measured disease 
specific quality of life indicated a statistical significant median 29% 
(P< 0.001, IQR 16% - 47%) improvement after 24 weeks of 
treatment. The strongest improvement of 39% was found in the 
domain fatigue. This was accompanied by an average 27% 
improvement in the SF36 measured general health related quality of 
life across all scales, with a near normalization of median scores on 
the role limitations due to physical health. All the changes per domain 





Table 1. Patient characteristics 
Patients n, 20 
Age Years 49 ± 12 
 Range 23-71 
Female n, % 11 (55%) 
Mast cell load parameters   
Tryptase μg/l 34 (24 – 41) 
Methylhistamine μm/mol cr. 344 (171 – 391) 
Methylimidazole acedic 
acid 
mm/mol cr. 4.5 (3.4 – 5.9) 
Urticaria Pigmentosa n, % 15 (75%) 
Hepatosplenomegaly n, % 3 (15%) 
Bone marrow mast cell infiltration   
Biopsy % mast cells 4.5 ( 2.0 – 7.5) 
Aspirate % mast cells 1.5 (1.0 – 3.0) 
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Figure 2:  Percentage change in mastocytosis symptom assessment 
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Figure 3: Symptom severity as measured by the mastocytosis 
symptom assessment form (MSAF) before and after 24 weeks of 
treatment with midostaurin, the higher the score, the more severe the 
symptoms.  
 
Biochemical and mast cell infiltration response 
After 24 weeks, a reduction of mast cell infiltration, as denoted by a 
sharp decrease in all mast cell load markers was found in 80% 
(n=16) of included patients. (Online supplementary Figure 1).   
Already after 4 weeks all 19 still included patients showed a 
statistically significant reduction in tryptase levels (from 36.0 to 15.5 
ug/l, P< 0.001) that remained stably reduced for all but 1 patient 
throughout the study (Figure 4). The increase in tryptase seen in the 
one patient followed an adverse event with associated dosage 
reduction of midostaurin.  
A similar rebound effect was observed in most patients during the 2 
month wash-out period.  At the end of the study, 8 out of 16 
histologically assessable bone marrow biopsies showed a reduction 




increase and 6 no change. Urticaria pigmentosa improved in 12 
(80%) of the 15 patients with skin symptoms, resulting in a 40% 
reduction in median SCORMA score with the strongest effect seen in 
the intensity of lesions. (Online supplementary Figure 1) 
Safety and tolerability 
Midostaurin was well tolerated; the most common adverse events 
were nausea (n=16, 80%), headache (n=10, 50%) diarrhea (n=7, 
35%), all grade 1-2. Midostaurin-related nausea responded well to 5-
HT3 receptor antagonist anti-emetic medication, but was necessary 
until the end of the study for all but 6 patients. In 3 female patients 
nausea was uncontrolled by anti-emetics (CTC grade 2) and these 
patients dropped out of the study. There was one SAE, anaphylaxis 
during lunch with collapse not objectified with tryptase, deemed to be 
probably not treatment related and two additional other grade 3-4 
adverse events (syncope and elevated ALT). Notably, there were no 
CTC grade >1 hematological adverse events. The frequencies of 
grade 2 AEs are shown in Table 2. 
Follow-up 
According to protocol, all patients stopped midostaurin at week 24. 
Next, a 2 month wash-out period gave the opportunity to document 
duration of response. It appeared that most patients experienced a 
rapid relapse of symptoms, accompanied by an increase in tryptase 
levels as well (Figure 4). Ten patients restarted midostaurin at twice 
100 mg and all showed an improvement of symptoms once more, 
accompanied by a reduction in tryptase in all but two patients (Figure 
4). It is too early to present more data on longer follow-up, which 
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Figure 4: Median scoring per domain of the disease specific 
Mastocytosis Quality of Life Questionaire (MQLQ) and the general 
Short Form Health Survey 36 (SF36) related quality of life, a higher 
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Table 2. Common adverse events, occurring in >10% of patients or 
CTC grade >2.  
Adverse event CTC grade 1-2 CTC Grade 3 
Nausea 16 (80%) 0 
Headache 10 (50%) 0 
Diarrhea 7 (35%) 0 
Elevated transaminases 7 (35%) 1 (5%) 
Fatigue 6 (30%) 0 
Urinary tract infection 3 (15%) 0 
Dizziness 3 (15%) 0 
Flu like symptoms 3 (15%) 0 
Anemia 3 (15%) 0 
Abdominal pain 2 (10%) 0 
Arthralgia 2 (10%) 0 
Vomiting 2 (10%) 0 
Anaphylaxis 0 1 (5%) 
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In this first trial to investigate the use of midostaurin in ISM patients, 
we found this drug to be effective in symptom and mast cell 
infiltration-reduction in the large majority of patients. Notably, the 
responses were fast and seen in traditionally refractory symptoms, 
such as fatigue, UP and musculoskeletal pain. The only symptom 
that did not react and even worsened was nausea, but we assume 
that this did not reflect disease activity, but was a well-known side 
effect of midostaurin. Due to the non-randomized nature of this trial 
the contribution of a placebo-effect to symptom reduction can’t be 
ruled out. However, the strong biochemical response suggestive of 
mast cell load reduction supports the notion that the observed clinical 
effect was due to mast cell targeting.  Notably, reductions in serum 
tryptase and the urinary histamine metabolites were more 
pronounced compared to the modest reduction in bone marrow and 
cutaneous mast cell infiltration. A possible explanation is that the 
early inhibiting effects of midostaurin on mast cell mediator synthesis 
and release are stronger than the anti-proliferative effects that will 
need more time than the 24 weeks of this trial.16 A mast cell mediator 
release inhibiting effect is further supported by the fast rebound effect 
in symptoms and tryptase levels after dosage reduction and during 
the wash-out phase. This suggests that the dose of twice 100 mg 
seems necessary, and moreover, that a duration of 24 weeks is not 
enough to stabilize the disease. This fast rebound of signs and 
symptoms is disappointing, but is a previously noted characteristic of 
tyrosine kinase inhibitors.25  Nevertheless, observations in CML 
patients treated with a Kit targeting tyrosine kinase inhibitor suggests 
that mast cell depletion occurs after 1 year of treatment.26 
Consequently, we hope that prolonged administration of midostaurin 
will enable some dose reduction.  
Patient selection for this trial was strict with only patients with 
severe refractory symptoms and serum tryptase > 20 ug/l accepted 
to maximize the possibility of finding a clinical or biochemical effect. 
To illustrate the relative rarity of this patient category, of the 168 
patients that filled out the screening questionnaire 94 did not have 
symptoms severe enough for inclusion and an additional 17 had 
insufficiently high tryptase levels (Figure 1). As such, the trial 
population is distinctly different from the average ISM patient. 




applicable than suggested by these numbers and recommend future 
trials to broaden the inclusion criteria. One caveat related to our strict 
patient selection is the possibility of regression to the mean of 
symptoms. However, all trial patients had their symptoms scored at 
least twice before the study at start – during pre-screening and at 
entry.  A post hoc analysis comparing symptom severity between the 
screening phase and the start of the trial did not find a significant 
difference in symptom severity over these 6+ months. Despite side 
effects, notably nausea, most patients favored continuation of the 
drug. As we used symptoms as primary endpoint, obviously any 
future phase III trial should include a placebo control arm.  
In conclusion, we find midostaurin to be an effective, fast 
acting, safe and reasonably well tolerated treatment modality for ISM 
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